(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -40.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Arvinas's revenue in 2025 is $372,800,000.On average, 7 Wall Street analysts forecast ARVN's revenue for 2025 to be $19,692,654,672, with the lowest ARVN revenue forecast at $17,987,310,775, and the highest ARVN revenue forecast at $22,465,784,070. On average, 7 Wall Street analysts forecast ARVN's revenue for 2026 to be $8,751,964,665, with the lowest ARVN revenue forecast at $4,992,396,460, and the highest ARVN revenue forecast at $12,609,471,941.
In 2027, ARVN is forecast to generate $7,993,193,820 in revenue, with the lowest revenue forecast at $2,405,160,412 and the highest revenue forecast at $14,442,709,288.